First, peripheral blood tumor biomarkers may be assessed at baseline before PSMA RPT to enhance PET-based imaging biomarkers and to narrow the suitability criteria, with an aim to refine patient selection for PSMA RPT. This evidence concerns the gene FOLH1 and neoplasm.